Michael DeMicco

1.7k total citations
20 papers, 1.1k citations indexed

About

Michael DeMicco is a scholar working on Hepatology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael DeMicco has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hepatology, 8 papers in Epidemiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael DeMicco's work include Hepatitis C virus research (12 papers), Hepatitis B Virus Studies (6 papers) and Gastric Cancer Management and Outcomes (4 papers). Michael DeMicco is often cited by papers focused on Hepatitis C virus research (12 papers), Hepatitis B Virus Studies (6 papers) and Gastric Cancer Management and Outcomes (4 papers). Michael DeMicco collaborates with scholars based in United States, United Kingdom and Germany. Michael DeMicco's co-authors include Eric Lawitz, Lawrence D. Wruble, Phillip Banks, Brinda Wiita, Stephan R. Targan, Michael Safdi, Julius Deren, Thom R. Nichols, Candis Fleishman and Charles A. Sninsky and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Michael DeMicco

20 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael DeMicco United States 12 636 548 216 214 179 20 1.1k
H. Porst Germany 12 590 0.9× 625 1.1× 130 0.6× 28 0.1× 16 0.1× 32 893
David Rowbotham New Zealand 16 330 0.5× 115 0.2× 266 1.2× 231 1.1× 3 0.0× 58 773
Zeki Karasu Türkiye 22 876 1.4× 886 1.6× 350 1.6× 10 0.0× 8 0.0× 107 1.4k
Fulya Günşar Türkiye 20 788 1.2× 794 1.4× 589 2.7× 32 0.1× 5 0.0× 91 1.5k
Vikram Narang India 14 235 0.4× 63 0.1× 219 1.0× 133 0.6× 7 0.0× 76 657
Chih‐Ming Liang Taiwan 17 120 0.2× 81 0.1× 539 2.5× 13 0.1× 33 0.2× 65 771
Nafiye Urgancı Türkiye 15 145 0.2× 79 0.1× 347 1.6× 70 0.3× 14 0.1× 83 727
Edgar Ayala Spain 10 629 1.0× 109 0.2× 566 2.6× 467 2.2× 2 0.0× 14 1.1k
H Telatar Türkiye 16 203 0.3× 291 0.5× 270 1.3× 37 0.2× 3 0.0× 53 686
Alexandra E. Read United States 12 565 0.9× 618 1.1× 309 1.4× 15 0.1× 3 0.0× 13 857

Countries citing papers authored by Michael DeMicco

Since Specialization
Citations

This map shows the geographic impact of Michael DeMicco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael DeMicco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael DeMicco more than expected).

Fields of papers citing papers by Michael DeMicco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael DeMicco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael DeMicco. The network helps show where Michael DeMicco may publish in the future.

Co-authorship network of co-authors of Michael DeMicco

This figure shows the co-authorship network connecting the top 25 collaborators of Michael DeMicco. A scholar is included among the top collaborators of Michael DeMicco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael DeMicco. Michael DeMicco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rex, Douglas K., Raj Bhandari, Taddese Desta, et al.. (2018). A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointestinal Endoscopy. 88(3). 427–437.e6. 196 indexed citations
2.
DeMicco, Michael, Lucy Clayton, Michael S. Epstein, et al.. (2017). Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate. Gastrointestinal Endoscopy. 87(3). 677–687.e3. 62 indexed citations
3.
DeMicco, Michael, et al.. (2017). Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therapeutic Advances in Gastroenterology. 10(11). 837–851. 52 indexed citations
4.
Garimella, Τushar, Wen‐Lin Luo, Philip Wastall, et al.. (2015). Assessment of Drug-Drug Interactions between Daclatasvir and Methadone or Buprenorphine-Naloxone. Antimicrobial Agents and Chemotherapy. 59(9). 5503–5510. 21 indexed citations
5.
Garimella, Τushar, Wen‐Lin Luo, Philip Wastall, et al.. (2014). Evaluation of drug‐drug interaction between daclatasvir and methadone or buprenorphine/naloxone. Journal of the International AIDS Society. 17(4S3). 19628–19628. 5 indexed citations
6.
Tatum, H., Paul J. Thuluvath, Eric Lawitz, et al.. (2014). A randomized, placebo‐controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis. 22(8). 658–664. 13 indexed citations
7.
Lawitz, Eric, John M. Hill, Bradley Vince, et al.. (2013). 847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS. Journal of Hepatology. 58. S347–S347. 5 indexed citations
8.
9.
Giri, Nagdeep, Anna Plotka, Yali Liang, et al.. (2013). Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.. Journal of Clinical Oncology. 31(15_suppl). 2568–2568. 2 indexed citations
10.
11.
Lawitz, Eric, John M. Hill, Thomas Marbury, et al.. (2012). A Phase I, Randomized, Placebo-Controlled, 3-Day, Ascending-Dose Study of Gs-9451, An Ns3/4A Protease Inhibitor, in Genotype 1 Hepatitis C Patients. Antiviral Therapy. 18(3). 311–319. 8 indexed citations
12.
Jacobson, Ira M., Eric Lawitz, Jacob Lalezari, et al.. (2012). 1120 PSI-7977 400 MG QD SAFETY AND TOLERABILITY IN THE FIRST 450 PATIENTS TREATED FOR 12 WEEKS. Journal of Hepatology. 56. S441–S441. 3 indexed citations
13.
Läwitz, E., Tarek Hassanein, Mitchell Davis, et al.. (2012). 1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?. Journal of Hepatology. 56. S1–S1. 22 indexed citations
14.
Kardos, Keith, Eugene R. Schiff, Karam Mounzer, et al.. (2010). Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. Journal of Virological Methods. 172(1-2). 27–31. 87 indexed citations
15.
Nettles, Richard E., Min Gao, Marc Bifano, et al.. (2010). Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 54(6). 1956–1965. 141 indexed citations
16.
Lawitz, Eric, M. Rodríguez‐Torres, Michael DeMicco, et al.. (2009). 1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology. 50. S384–S384. 32 indexed citations
17.
Wruble, Lawrence D., Michael DeMicco, Jeffrey Medoff, et al.. (2006). Residue-free sodium phosphate tablets (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial. Gastrointestinal Endoscopy. 65(4). 660–670. 26 indexed citations
18.
19.
20.
Safdi, Michael, Michael DeMicco, Charles A. Sninsky, et al.. (1995). A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Gastroenterology. 108(4). A909–A909. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Porst Breakdown of academic impact, for papers by David Rowbotham Breakdown of academic impact, for papers by Zeki Karasu Breakdown of academic impact, for papers by Fulya Günşar Breakdown of academic impact, for papers by Vikram Narang Breakdown of academic impact, for papers by Chih‐Ming Liang Breakdown of academic impact, for papers by Nafiye Urgancı Breakdown of academic impact, for papers by Edgar Ayala Breakdown of academic impact, for papers by H Telatar Breakdown of academic impact, for papers by Alexandra E. Read
Rankless by CCL
2026